BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sasaki R, Kanda T, Nakamoto S, Haga Y, Nakamura M, Yasui S, Jiang X, Wu S, Arai M, Yokosuka O. Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol 2015; 7(8): 1125-1132 [PMID: 26052401 DOI: 10.4254/wjh.v7.i8.1125] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Hummell NA, Revtovich AV, Kirienko NV. Novel Immune Modulators Enhance Caenorhabditis elegans Resistance to Multiple Pathogens. mSphere 2021;6:e00950-20. [PMID: 33408224 DOI: 10.1128/mSphere.00950-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World J Gastroenterol 2017; 23(46): 8120-8127 [PMID: 29290649 DOI: 10.3748/wjg.v23.i46.8120] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kazakov AS, Sofin AD, Avkhacheva NV, Denesyuk AI, Deryusheva EI, Rastrygina VA, Sokolov AS, Permyakova ME, Litus EA, Uversky VN, Permyakov EA, Permyakov SE. Interferon Beta Activity Is Modulated via Binding of Specific S100 Proteins. Int J Mol Sci 2020;21:E9473. [PMID: 33322098 DOI: 10.3390/ijms21249473] [Reference Citation Analysis]
4 Sasaki R, Kanda T, Yasui S, Haga Y, Nakamura M, Yamato M, Wu S, Nakamoto S, Arai M, Mikami S, Miyauchi H, Matsubara H, Yokosuka O. Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation. Case Rep Gastroenterol 2016;10:248-56. [PMID: 27462193 DOI: 10.1159/000445374] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Grubczak K, Grzeszczuk A, Groth M, Hryniewicz A, Kretowska-Grunwald A, Flisiak R, Moniuszko M. Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients. Viruses 2021;13:1448. [PMID: 34452314 DOI: 10.3390/v13081448] [Reference Citation Analysis]
6 Sasaki R, Kanda T, Kato N, Yokosuka O, Moriyama M. Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response. World J Hepatol 2018; 10(12): 898-906 [PMID: 30631394 DOI: 10.4254/wjh.v10.i12.898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Ward T, Webster S, Mishina S, McEwan P, Wygant G, Wang F. Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan. Value Health Reg Issues. 2017;12:1-6. [PMID: 28648305 DOI: 10.1016/j.vhri.2016.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]